Clinical Trials

GastrointestinalGynecologicThoracic

750 enrolled

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06843447 2026-05-26

MK-5909-003

Phase 1/2 Recruiting

460 enrolled

Ovarian Cancer Recurrent

NCT07061977 2026-05-26

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

336 enrolled

Phase 2 Not yet recruiting

Locally Advanced Cervical Adenocarcinoma

NCT07495124 2026-05-26

IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence

26 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06952504 2026-05-22

TroFuse-033

1,123 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT07216703 2026-05-22

TroFuse-036

1,023 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT05819892 2026-05-20

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Phase 1 Recruiting

21 enrolled

Endometrial Neoplasms

NCT07024784 2026-05-19

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Phase 2 Recruiting

377 enrolled

Fallopian Tube Neoplasms, Neoplasms

NCT05255653 2026-05-15

RAINBO

Phase 2/3 Recruiting

1,615 enrolled

Endometrial Neoplasms

NCT01081951 2026-05-13

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

162 enrolled 15 charts

Ovarian Neoplasms

NCT04274426 2026-05-13

MIROVA

136 enrolled

Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma

NCT06890338 2026-05-13

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Phase 2 Recruiting

140 enrolled

Phase 2 Not yet recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT07504588 2026-05-13

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

87 enrolled

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

NCT02264678 2026-05-12

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

354 enrolled

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Ovarian Neoplasms

NCT04389632 2026-05-11

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Phase 1 Recruiting

1,006 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT03932409 2026-05-08

FIERCE

45 enrolled

Endometrial Neoplasms

NCT06989112 2026-05-06

DE-01

600 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

NCT05173987 2026-05-05

KEYNOTE-C93

280 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT06466382 2026-05-05

OVPrecision

Phase NA Recruiting

60 enrolled

Fallopian Tube Neoplasms

NCT01167712 2026-05-04

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

692 enrolled 11 charts

Brenner Tumor, Fallopian Tube Neoplasms

NCT02446600 2026-05-04

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

579 enrolled 17 charts

Phase 1/2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03393884 2026-05-04

OVATION 2

130 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT03740165 2026-05-04

KEYLYNK-001

Phase 3 Completed

1,367 enrolled 29 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT03914612 2026-05-04

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

813 enrolled 16 charts 1 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT05739981 2026-05-04

MRD

Phase 1/2 Recruiting

30 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06915025 2026-05-04

OVATION-3

500 enrolled

Phase 3 Not yet recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07564141 2026-05-04

RAINFOL™-07

688 enrolled

Ovarian Neoplasms

NCT01081262 2026-04-30

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

50 enrolled 13 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00977574 2026-04-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

349 enrolled 11 charts

GynecologicSarcoma

Endometrial Adenocarcinoma

NCT03556839 2026-04-21

BEATcc

Phase 3 Completed

410 enrolled

GastrointestinalGynecologic

Carcinoma, Uterine Cervical Neoplasms

NCT04615013 2026-04-16

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

Phase 1 Recruiting

24 enrolled

Cervical Esophagus Adenocarcinoma

NCT07168200 2026-04-15

A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer

720 enrolled

GastrointestinalGenitourinaryGynecologicThoracic

Advanced Cervical Cancer

NCT01352962 2026-04-14

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

Phase 1 Completed

18 enrolled

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT03786081 2026-04-14

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Phase 1/2 Terminated

214 enrolled

Uterine Cervical Neoplasms

NCT01244789 2026-04-13

Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer

244 enrolled

Endometrial Neoplasms

NCT01366144 2026-04-13

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction